Amarin Corp Plc (AMRN)

[mtds]

Agree 100%-- JELIS study -analysis article in 2011 by Horoshige and Yokoyama et.el in Atheroscelerosis,Thrombosis Journl Vol.18,No.2 is a big article with data--Inflammation causes CV events.
AA/EPA ratio dropped from 1.6 to 0.8 after the study. Dr.Barry Sears sent me this reference-- His book Zone-Diet sold 2 mil.copies--says that AA/EPA is a predictor of future C-RP--which is used to measure inflammation.
Crestor did well in Jupiter study because they selected people with high C-RP-avg. of 4.3 and all were above 2.0.
Vascepa lowers C-RP by 22%.
You are right--Vascepa's benefits come from its ability to lower C-RP.
KEY is: REDUCE-IT study early results.
Cardiologists at Cleveland Clinic,Mayo,Yale,Harvard respect Dr.Bhatt of Harvard who is supervising this study.
I received a comment from 3 top Cardiologists in USA--all awaiting Reduce-It study results.
Can you find out: When to expect early results for Reduce-IT--in 2014?
By the way--Joseph Anderson of Abingworth is retiring as a director.Are they selling their 8 mil.shares?
Carl Gordon of Orbimed is retiring-but he sold their shares in 2011.